ERCC polymorphisms and prognosis of patients with osteosarcoma
详细信息 查看全文
- 作者：Jinsong Li (1)
Shaohua Liu (2)
Weiguo Wang (1)
Kexiang Zhang (1)
Zhendong Liu (1)
Chaoyue Zhang (1)
Shijie Chen (1)
Song Wu (1) - 关键词：ERCC ; Osteosarcoma ; Polymorphisms ; Prognosis
- 刊名：Tumor Biology
- 出版年：2014
- 出版时间：October 2014
- 年：2014
- 卷：35
- 期：10
- 页码：10129-10136
- 全文大小：329 KB
- 参考文献：1. Hattinger CM, Pasello M, Ferrari S, Picci P, Serra M. Emerging drugs for high-grade osteosarcoma. Expert Opin Drug Saf. 2010;15:615-4.
2. Marina N, Gebhardt M, Teot L, Gorlick R. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist. 2004;9:422-1. CrossRef
3. Fletcher CD, Unni KK, Mertens F: Pathology and genetics of tumours of soft tissue and bone. Iarc, 2002.
4. Bai SB, Chen HX, Bao YX, Luo X, Zhong JJ. Predictive impact of common variations in DNA repair genes on clinical outcome of osteosarcoma. Asian Pacific journal of cancer prevention : APJCP. 2013;14:3677-0. CrossRef
5. Chou AJ, Gorlick R. Chemotherapy resistance in osteosarcoma: Current challenges and future directions. Expert Rev Anticancer Ther. 2006;6:1075-5. CrossRef
6. Longhi A, Errani C, De Paolis M, Mercuri M, Bacci G. Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev. 2006;32:423-6. CrossRef
7. Sun XH, Hou WG, Zhao HX, Zhao YL, Ma C, Liu Y. Single nucleotide polymorphisms in the NER pathway and clinical outcome of patients with bone malignant tumors. Asian Pacific journal of cancer prevention: APJCP. 2013;14:2049-2. CrossRef
8. Goode EL, Ulrich CM, Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2002;11:1513-0.
9. Jones AR, Bell-Horwath TR, Li G, Rollmann SM, Merino EJ. Novel oxidatively activated agents modify DNA and are enhanced by ERCC1 silencing. Chem Res Toxicol. 2012;25:2542-2. CrossRef
10. Shannon M, Lamerdin JE, Richardson L, McCutchen-Maloney SL, Hwang MH, Handel MA, et al. Characterization of the mouse xpf DNA repair gene and differential expression during spermatogenesis. Genomics. 1999;62:427-5. CrossRef
11. Lu B, Li J, Gao Q, Yu W, Yang Q, Li X. Laryngeal cancer risk and common single nucleotide polymorphisms in nucleotide excision repair pathway genes ercc1, ercc2, ercc3, ercc4, ercc5 and xpa. Gene. 2014;542:64-. CrossRef
12. Wu Y, Yang Y: Complex association between ercc2 gene polymorphisms, gender, smoking and the susceptibility to bladder cancer: A meta-analysis. Tumor Biology 2014;35:1-3.
13. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603-. CrossRef
14. Higgins J, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539-8. CrossRef
15. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. Br Med J. 2003;327:557. CrossRef
16. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-4. CrossRef
17. Stuck AE, Rubenstein LZ, Wieland D. Bias in meta-analysis detected by a simple, graphical test. Asymmetry detected in funnel plot was probably due to true heterogeneity BMJ. Br Med J. 1998;316:469. CrossRef
18. Yang L-M, Li X-H, Bao C-F. Glutathione s-transferase p1 and DNA polymorphisms with the response to chemotherapy and the prognosis of bone tumor. Asian Pacific Journal of Cancer Prevention. 2012;13:5883-.- 作者单位：Jinsong Li (1)
Shaohua Liu (2)
Weiguo Wang (1)
Kexiang Zhang (1)
Zhendong Liu (1)
Chaoyue Zhang (1)
Shijie Chen (1)
Song Wu (1)
1. Department of Orthopaedics, The Third Xiangya Hospital of Central South University, Changsha, Hunan, China
2. Department of Spine Surgery, The Xiangya Hospital of Central South University, Changsha, Hunan, China- ISSN：1423-0380
- 作者单位：Jinsong Li (1)
文摘
Osteosarcoma is the most common primary bone malignancy in children and teenagers, and its clinical outcome remains poor. Previous studies have investigated the association between excision repair cross-complementing (ERCC) and prognosis of osteosarcoma patients, but their results were inconsistent. We aimed to clarify the associations between ERCC polymorphisms and osteosarcoma prognosis by using meta-analysis. We searched relevant studies in PubMed, Embase, coupled with Chinese National Knowledge Infrastructure (CNKI) in human osteosarcoma published prior to April, 2014. Hazard ratios (HR) together with their 95?% confidence intervals (95?% CI) were used to measure the relationship between ERCC mutations and prognosis in patients with osteosarcoma. Pooled results showed that polymorphism of ERCC2 Lys751Gln was associated with the overall survival of osteosarcoma (GG vs. AA, HR--.40; 95?% CI 0.18-.86), and ERCC5 His46His mutation was associated with the event-free survival of osteosarcoma (CC vs. TT, HR--.37; 95?% CI 0.15, 0.93). In addition, there is no evidence of association on ERCC1 Asn118Asn, ERCC1 Gln504Lys, and ERCC2 Asp312Asn polymorphisms with prognosis in osteosarcoma. In summary, the ERCC2 Lys751Gln and ERCC5 His46His polymorphisms might influence osteosarcoma prognosis.